Mkt Cap$2.23T-2.09%
24h Vol$74.03B
BTC Dom56.2%
ETH Dom9.0%
F&G23Extreme Fear
BTC$62,495.00-2.10% ETH$1,662.50-3.31% USDT$0.99890.00% BNB$576.53-2.03% USDC$0.9998-0.01% XRP$1.11-1.51% SOL$69.43-3.23% TRX$0.329-1.30% FIGR_HELOC$1.03-0.16% HYPE$62.14-5.95% DOGE$0.0788-3.89% USDS$0.9997+0.01% RAIN$0.0156-2.27% LEO$9.54+0.05% ZEC$416.96-5.64% XLM$0.1953-3.57% BTC$62,495.00-2.10% ETH$1,662.50-3.31% USDT$0.99890.00% BNB$576.53-2.03% USDC$0.9998-0.01% XRP$1.11-1.51% SOL$69.43-3.23% TRX$0.329-1.30% FIGR_HELOC$1.03-0.16% HYPE$62.14-5.95% DOGE$0.0788-3.89% USDS$0.9997+0.01% RAIN$0.0156-2.27% LEO$9.54+0.05% ZEC$416.96-5.64% XLM$0.1953-3.57%
News

COGT

Total Stories
1
Section
COGT
Cogent Biosciences Stock Soars 120% on Positive Phase 3 PEAK Trial Results
Market Analysis

Cogent Biosciences Stock Soars 120% on Positive Phase 3 Cancer Drug Results

Cogent Biosciences stock jumped 120% after positive Phase 3 PEAK trial results for its GIST drug bezuclastinib.

Tim FriesNov 10, 20254 min read